Stryker Co. (NYSE:SYK) Shares Purchased by FUKOKU MUTUAL LIFE INSURANCE Co

FUKOKU MUTUAL LIFE INSURANCE Co increased its holdings in shares of Stryker Co. (NYSE:SYK) by 23.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,721 shares of the medical technology company’s stock after acquiring an additional 324 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Stryker were worth $620,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Mn Services Vermogensbeheer B.V. grew its holdings in Stryker by 2.3% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 135,100 shares of the medical technology company’s stock valued at $48,643,000 after purchasing an additional 3,100 shares during the last quarter. New York Life Investment Management LLC grew its holdings in Stryker by 0.9% in the fourth quarter. New York Life Investment Management LLC now owns 46,144 shares of the medical technology company’s stock valued at $16,614,000 after purchasing an additional 390 shares during the last quarter. NewEdge Wealth LLC grew its holdings in Stryker by 10.5% in the fourth quarter. NewEdge Wealth LLC now owns 6,250 shares of the medical technology company’s stock valued at $2,250,000 after purchasing an additional 595 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in Stryker in the fourth quarter valued at $169,000. Finally, Checchi Capital Advisers LLC grew its holdings in Stryker by 1.4% in the fourth quarter. Checchi Capital Advisers LLC now owns 4,024 shares of the medical technology company’s stock valued at $1,449,000 after purchasing an additional 56 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $391.54 on Thursday. The stock’s 50-day moving average is $379.42 and its 200-day moving average is $370.37. The company has a market cap of $149.40 billion, a price-to-earnings ratio of 50.46, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of several research reports. Wells Fargo & Company upped their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Evercore ISI upped their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Argus set a $450.00 price objective on Stryker in a research report on Monday, February 3rd. Robert W. Baird upped their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.